Picture loading failed.

Anti-Heat Shock Protein 90 Homolog therapeutic antibody (Pre-made Efungumab biosimilar,scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Efungumab (trade name Mycograb) was a drug developed by NeuTec Pharma (a subsidiary of Novartis), intended to treat candidemia (a bloodstream infection caused by pathogenic yeast) in combination with amphotericin B. The European Medicines Agency has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-167-1mg 1mg 3090
GMP-Bios-ab-167-10mg 10mg 21890
GMP-Bios-ab-167-100mg 100mg 148000
GMP-Bios-ab-167-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-Heat Shock Protein 90 Homolog therapeutic antibody (Pre-made Efungumab biosimilar,scFv)
INN Name Efungumab
TargetHeat Shock Protein 90 Homolog
Species ReactivityHuman
CH1 Isotypena
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2006
Year Recommended2007
CompaniesNeuTec Pharma
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedBreast cancer;Candidiasis
Development Techna